Peregrine Pharmaceuticals has been awarded a grant totaling $585,000 to its collaborators at the University of Texas Southwestern Medical Center at Dallas to conduct preclinical studies of Tarvacin Anti-Cancer as a potential treatment for prostate cancer. Tarvacin Anti-Cancer, Peregrine’s lead vascular targeting antibody, is currently in a Phase I clinical trial for advanced refractory solid tumors. In November, Peregrine received a major DOD prostate cancer grant to UT Southwestern r...